Nuvation Bio Inc. (NUVB) stock
NUVBNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 4/30107% above fair value
$3.90+0.06 (+1.56%)
Close on Nov 17, 2026Market cap $1.37BP/E –Yield –
Nuvation Bio price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Nuvation Bio's price to sales ratio was 8.7× on Nov 11, 2026, against 101.4× a year earlier. Over the last 2 years it ranged from 8.7× to 451.0×, with a median of 69.9×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 8.7× | −104.4 |
| 2025 | Dec 31, 2025 | 113.2× | −300.5 |
| 2024 | Dec 31, 2024 | 413.7× | – |
See a number that looks wrong?